A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Emapalumab (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Adverse reactions
- Sponsors Light Chain Bioscience
- 31 Aug 2018 Biomarkers information updated
- 22 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2020.
- 22 Feb 2018 Planned number of patients changed from 35 to 55.